2023-01-09 14578273 2024-01-31 14578273 2023-01-09 2024-01-31 14578273 uk-core:WithinOneYear 2024-01-31 14578273 uk-core:ShareCapital 2024-01-31 14578273 uk-core:RetainedEarningsAccumulatedLosses 2024-01-31 14578273 uk-bus:Director1 2023-01-09 2024-01-31 iso4217:GBP xbrli:pure 14578273 uk-bus:AuditExemptWithAccountantsReport 2023-01-09 2024-01-31 14578273 uk-bus:FRS102 2023-01-09 2024-01-31 14578273 uk-bus:FilletedAccounts 2023-01-09 2024-01-31 14578273 uk-bus:PrivateLimitedCompanyLtd 2023-01-09 2024-01-31
JEMIMAPHARMA LIMITED
Registered Number:14578273
For the period 09 January 2023 to 31 January 2024
England and Wales
Unaudited Financial Statements
2
For the period 09 January 2023 to 31 January 2024
JEMIMAPHARMA LIMITED
Contents Page
1
Statement of Financial Position
2 to 3
Notes to the Financial Statements
3
Registered Number :
14578273
As at 31 January 2024
JEMIMAPHARMA LIMITED
Statement of Financial Position
£
2024
Notes
Fixed assets
Property, plant and equipment
14,219
2
14,219
Current assets
Trade and other receivables
6,000
3
Cash and cash equivalents
19,654
25,654
Trade and other payables: amounts falling due within one
year
(31,755)
4
(6,101)
Net current liabilities
Total assets less current liabilities
8,118
8,118
Net assets/liabilities
Capital and reserves
Called up share capital
100
Retained earnings
8,018
8,118
Shareholders' funds
For the period 09 January 2023 to 31 January 2024 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the period 09 January 2023 to 31 January 2024 in accordance with Section 476 of the Companies Act 2006
The director acknowledges her responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
each financial year and of its profit or loss for each financial year in accordance with the requirements of Section
394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
statements, so far as applicable to the company.
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
HEENA JEMIMA CHOWDRY Director
These financial statements were approved and authorised for issue by the Board on 08 October 2024 and were signed by:
The notes form part of these financial statements
1 of 3
4
For the period 09 January 2023 to 31 January 2024
JEMIMAPHARMA LIMITED
Notes to the Financial Statements
Statutory Information
JEMIMAPHARMA LIMITED is a private limited company, limited by shares, domiciled in England and Wales,
registration number 14578273.
Registered address:
THE RECTORY CHURCH LANE
NORTH OCKENDON
UPMINSTER
ESSEX
RM14 3QH
The presentation currency is £ sterling.
1. Accounting policies
Basis of preparing the financial statements
2. Property, plant and equipment
Furniture and
Fittings
£
Cost or
valuation
16,728
Additions
At 31 January 2024
16,728
Provision for depreciation and impairment
Charge for period
2,509
At 31 January 2024
2,509
At 31 January 2024
Net book value
14,219
3. Trade and other receivables
2024
£
Trade debtors
6,000
4. Trade and other payables: amounts falling due within one year
2024
£
Taxation and social security
2,594
Other creditors
29,161
31,755
2 of 3
5
For the period 09 January 2023 to 31 January 2024
JEMIMAPHARMA LIMITED
Notes to the Financial Statements Continued
5. Average number of persons employed
During the year the average number of employees was 2
3 of 3